iRhythm Technologies, Inc.

NasdaqGS IRTC

iRhythm Technologies, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD 511.86 M

iRhythm Technologies, Inc. Net Cash Used Provided By Financing Activities is USD 511.86 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 5,921.91% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • iRhythm Technologies, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 8.50 M, a -64.49% change year over year.
  • iRhythm Technologies, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 23.94 M, a 192.11% change year over year.
  • iRhythm Technologies, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -25.99 M, a -112.11% change year over year.
  • iRhythm Technologies, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 214.55 M, a 93.05% change year over year.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
Loading...
NasdaqGS: IRTC

iRhythm Technologies, Inc.

CEO Mr. Quentin S. Blackford
IPO Date Oct. 20, 2016
Location United States
Headquarters 699 8th Street
Employees 2,000
Sector Health Care
Industries
Description

iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Similar companies

FNA

Paragon 28, Inc.

USD 10.28

-4.28%

OFIX

Orthofix Medical Inc.

USD 17.51

0.81%

GKOS

Glaukos Corporation

USD 147.95

-2.58%

NPCE

NeuroPace, Inc.

USD 11.84

-2.23%

SGHT

Sight Sciences, Inc.

USD 3.15

-2.78%

BRKR

Bruker Corporation

USD 61.26

-2.69%

SRDX

Surmodics, Inc.

USD 35.55

-0.81%

CNMD

CONMED Corporation

USD 67.79

-2.46%

LIVN

LivaNova PLC

USD 47.63

0.66%

ELMD

Electromed, Inc.

USD 31.05

1.90%

ITGR

Integer Holdings Corporation

USD 138.83

2.72%

KIDS

OrthoPediatrics Corp.

USD 23.55

-5.80%

StockViz Staff

January 15, 2025

Any question? Send us an email